Skip to main content

Mature cannabis plants are seen at the CannTrust Niagara Greenhouse Facility in Fenwick, Ont., on June 26, 2018.

Tijana Martin/The Canadian Press

Additional reporting from Cannabis Professional and Report on Business

CannTrust Holdings Inc. is laying off about 180 people – about 20 per cent of the Ontario-based cannabis producer’s work force – following repeated problems with both its product and how it has been produced.

The move is expected to result in annual cash savings of about $9-million, as well as the company recording roughly $2-million in severance costs, the company said.

Most of the affected employees were in cultivation and customer-service support roles.

Story continues below advertisement

“We have made the extremely difficult decision to restructure our workforce to reflect the current requirements of our business,” said Robert Marcovitch, interim chief executive of CannTrust in a statement.

In August, the Ontario government’s cannabis retailer said it would return almost $3-million worth of cannabis to the company after determining that some of the products didn’t live up to the terms of its supply agreement.

The move by the provincial Crown corporation in charge of wholesale distribution and online pot retail was the latest setback for the cannabis producer, which continues to be under investigation by Health Canada.

In July, CannTrust disclosed the federal regulator’s findings that the company was growing cannabis in unlicensed rooms in its greenhouse in Pelham, Ont.

Health Canada placed a hold on CannTrust’s inventory amounting to approximately 5,200 kilograms of dried cannabis. The company also instituted a voluntary hold of approximately 7,500 kilograms of dried cannabis equivalent.

CannTrust later voluntarily suspended all sales and distribution of its products as a precaution while regulators investigate its Vaughan, Ont.-based manufacturing facility.

Also in August, the company said Health Canada notified CannTrust that its Vaughan facility was rated as non-compliant as well. CannTrust also in August said that the Ontario Securities Commission had opened an investigation into issues around the alleged unlicensed growing at its Pelham greenhouse.

Story continues below advertisement

CannTrust has noted that Health Canada has not ordered a recall on any of the company’s products.

The company said it is taking steps to solve its regulatory problems.

A board committee is looking into the extent of the non-compliance and guiding efforts to fix it. The chief executive officer and board chairman have been replaced.

Shipments of all cannabis products have been stopped and the company said it is developing a plan to comply with Health Canada requirements.

Other provinces have said they’ll wait for the results of Health Canada’s review before returning any of the company’s product.

Go deeper into the industry with Cannabis Professional, The Globe and Mail's authoritative subscription news service.


Buy Now Start your 14-day trial
Report an error
Tickers mentioned in this story
Unchecking box will stop auto data updates
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter